



C3G Satellite Meeting Friday, September 8th 2017, Copenhagen, Denmark

VENUE: Hotel Scandic Copenhagen, Vester Søgade 6, 1601 Copenhagen, Denmark
5 minutes' walk from Copenhagen Central Station

REGISTRATION: <https://www.etches.com/emchd>

QUESTIONS ABOUT THE C3G SATELLITE MEETING: Richard Smith at richard-smith@uiowa.edu or Matthew Pickering at matthew.pickering@imperial.ac.uk
LOCAL CONGRESS ORGANISER: The Meeting Planners, info@meetingplanners.dk

7:30-8:15 Registration and Coffee		
8:15-8:20 Welcome and Introduction		
Aims and Objectives	Matthew Pickering	5 min
8:20-9:25 Renal Pathology: What it does and does not tell us Facilitator: Matthew Pickering		
C3 glomerulopathy – what have we learnt from the renal biopsy?	Vivette D'Agati	15 min
C3G natural history: insights from IgA nephropathy	Terry Cook	15 min
Areas of controversy – role of C4, C3G without C3	Sanjeev Sethi	15 min
Panel and Group Discussion		20 min
9:25-10:30 Biomarkers and Mechanisms Facilitator: Marina Noris		
Complement proteins as biomarkers – can they curtail the need for renal biopsy?	Richard Smith	15 min



Update on the drivers of disease: autoimmunity and paraproteins	Véronique Fremeaux-Bacchi	15 min
Update on the drivers of disease: the genes	Santiago Rodriguez de Córdoba	15 min
Panel and Group Discussion		20 min
10:30-11:00 Coffee Break		
11:00-12:05 The relevance of the glycomatrix to C3G Facilitator: Johan Van der Vlag		
The Glycocalyx – an overview	Johan Van der Vlag	15 min
Complement regulation in the extracellular matrix and glycomatrix	Anna Blom	15 min
Modelling complement activity on the extracellular matrix using MaxGel and microarrays	Mihály Józsi	15 min
Panel and Group Discussion	What are the key research questions?	20 min
12:05-13:15 Lunch		
13:15-14:45 Clinical Phenotype: Challenges and messages from the clinic Facilitator: Gerald Appel		
England	David Kavanagh	15 min
Italy	Giuseppe Remuzzi	15 min
US	Carla Nester	15 min
France	Fadi Fakhouri	15 min
Panel and Group Discussion		30 min
14:45-15:00 Coffee Break		



15:00-17:00
Treatment Strategies
Facilitator: Richard Smith

When would we use eculizumab in C3G?	Gerald Appel	20 min
Targeting C3	John Lambris (Amyndas)	20 min
Targeting factor D	Hetal Kocinsky (Achillion)	20 min
Targeting factor B	Anna Schubart (Novarits)	20 min
Targeting factor H and the FHR proteins	Peter Zipfel	20 min
Panel and Group Discussion		20 min

17:00-17:05
Summary

Closing remarks	Richard Smith	5 min
-----------------	---------------	-------